The role of radiation therapy in the treatment of multiple myeloma, plasmacytoma, and other plasma cell disorders

Prashant Kapoor; James A. Martenson

doi:10.1007/978-1-4614-8520-9_19

The role of radiation therapy in the treatment of multiple myeloma, plasmacytoma, and other plasma cell disorders

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Plasma cell malignancies are radioresponsive. Radiation is used as primary or adjunctive therapy of plasma cell disorders (PCDs). Palliation of symptoms is the commonest indication for radiation to the skeletal and soft tissue myelomatous lesions. Other indications include pretransplant conditioning, myeloma-related cord compression, or impending pathological fractures. Radiation is also utilized in the management of solitary osseous and extramedullary plasmacytomas, POEMS syndrome with a limited number of lesions, localized AL amyloidosis and rarely, Waldenström’s macroglobulinemia. Anecdotal reports outlining successful use of radiation with novel anti-myeloma agents exist. This chapter focuses on conventional radiation and chemo-radiation-based management strategies in PCDs.

Original language	English (US)
Title of host publication	Multiple Myeloma
Subtitle of host publication	Diagnosis and Treatment
Publisher	Springer New York
Pages	233-244
Number of pages	12
ISBN (Electronic)	9781461485209
ISBN (Print)	9781461485193
DOIs	https://doi.org/10.1007/978-1-4614-8520-9_19
State	Published - Jan 1 2014

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-4614-8520-9_19

Cite this

@inbook{3ae8fbaf2eb94bfa94ef5e2b68e12dc2,

title = "The role of radiation therapy in the treatment of multiple myeloma, plasmacytoma, and other plasma cell disorders",

abstract = "Plasma cell malignancies are radioresponsive. Radiation is used as primary or adjunctive therapy of plasma cell disorders (PCDs). Palliation of symptoms is the commonest indication for radiation to the skeletal and soft tissue myelomatous lesions. Other indications include pretransplant conditioning, myeloma-related cord compression, or impending pathological fractures. Radiation is also utilized in the management of solitary osseous and extramedullary plasmacytomas, POEMS syndrome with a limited number of lesions, localized AL amyloidosis and rarely, Waldenstr{\"o}m{\textquoteright}s macroglobulinemia. Anecdotal reports outlining successful use of radiation with novel anti-myeloma agents exist. This chapter focuses on conventional radiation and chemo-radiation-based management strategies in PCDs.",

author = "Prashant Kapoor and Martenson, {James A.}",

note = "Publisher Copyright: {\textcopyright} Mayo Foundation for Medical Education and Research 2014.",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/978-1-4614-8520-9_19",

language = "English (US)",

isbn = "9781461485193",

pages = "233--244",

booktitle = "Multiple Myeloma",

publisher = "Springer New York",

}

TY - CHAP

T1 - The role of radiation therapy in the treatment of multiple myeloma, plasmacytoma, and other plasma cell disorders

AU - Kapoor, Prashant

AU - Martenson, James A.

N1 - Publisher Copyright: © Mayo Foundation for Medical Education and Research 2014.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Plasma cell malignancies are radioresponsive. Radiation is used as primary or adjunctive therapy of plasma cell disorders (PCDs). Palliation of symptoms is the commonest indication for radiation to the skeletal and soft tissue myelomatous lesions. Other indications include pretransplant conditioning, myeloma-related cord compression, or impending pathological fractures. Radiation is also utilized in the management of solitary osseous and extramedullary plasmacytomas, POEMS syndrome with a limited number of lesions, localized AL amyloidosis and rarely, Waldenström’s macroglobulinemia. Anecdotal reports outlining successful use of radiation with novel anti-myeloma agents exist. This chapter focuses on conventional radiation and chemo-radiation-based management strategies in PCDs.

AB - Plasma cell malignancies are radioresponsive. Radiation is used as primary or adjunctive therapy of plasma cell disorders (PCDs). Palliation of symptoms is the commonest indication for radiation to the skeletal and soft tissue myelomatous lesions. Other indications include pretransplant conditioning, myeloma-related cord compression, or impending pathological fractures. Radiation is also utilized in the management of solitary osseous and extramedullary plasmacytomas, POEMS syndrome with a limited number of lesions, localized AL amyloidosis and rarely, Waldenström’s macroglobulinemia. Anecdotal reports outlining successful use of radiation with novel anti-myeloma agents exist. This chapter focuses on conventional radiation and chemo-radiation-based management strategies in PCDs.

UR - http://www.scopus.com/inward/record.url?scp=84956493489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956493489&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8520-9_19

DO - 10.1007/978-1-4614-8520-9_19

M3 - Chapter

AN - SCOPUS:84956493489

SN - 9781461485193

SP - 233

EP - 244

BT - Multiple Myeloma

PB - Springer New York

ER -

The role of radiation therapy in the treatment of multiple myeloma, plasmacytoma, and other plasma cell disorders

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this